Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Highlights
In virologically suppressed patients, switching to DRV/r monotherapy maintains HIV RNA suppression, and could lower treatment costs
During the MONET trial, the mean annual per-patient cost of antiretrovirals was €9915 in the triple therapy arm, of which 45% was from NRTIs and 55% from PIs
We estimated 65,000 people treated with antiretrovirals in Spain (50% NNRTI based, 50% PI based) and 15% of patients (9,750) eligible for PI monotherapy
Summary
In virologically suppressed patients, switching to DRV/r monotherapy maintains HIV RNA suppression, and could lower treatment costs. Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices JR Arribas1*, A Hill2, I Garcia3, A Anceau4
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
